1. Home
  2. ALTO vs SLN Comparison

ALTO vs SLN Comparison

Compare ALTO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALTO
  • SLN
  • Stock Information
  • Founded
  • ALTO 2003
  • SLN 1994
  • Country
  • ALTO United States
  • SLN United Kingdom
  • Employees
  • ALTO N/A
  • SLN N/A
  • Industry
  • ALTO Major Chemicals
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALTO Industrials
  • SLN Health Care
  • Exchange
  • ALTO Nasdaq
  • SLN Nasdaq
  • Market Cap
  • ALTO 123.0M
  • SLN 123.3M
  • IPO Year
  • ALTO N/A
  • SLN N/A
  • Fundamental
  • Price
  • ALTO $0.80
  • SLN $3.14
  • Analyst Decision
  • ALTO Strong Buy
  • SLN Buy
  • Analyst Count
  • ALTO 1
  • SLN 5
  • Target Price
  • ALTO $5.50
  • SLN $40.80
  • AVG Volume (30 Days)
  • ALTO 733.6K
  • SLN 292.1K
  • Earning Date
  • ALTO 05-05-2025
  • SLN 05-15-2025
  • Dividend Yield
  • ALTO N/A
  • SLN N/A
  • EPS Growth
  • ALTO N/A
  • SLN N/A
  • EPS
  • ALTO N/A
  • SLN N/A
  • Revenue
  • ALTO $965,258,000.00
  • SLN $43,258,000.00
  • Revenue This Year
  • ALTO N/A
  • SLN N/A
  • Revenue Next Year
  • ALTO $5.90
  • SLN N/A
  • P/E Ratio
  • ALTO N/A
  • SLN N/A
  • Revenue Growth
  • ALTO N/A
  • SLN 36.71
  • 52 Week Low
  • ALTO $0.76
  • SLN $1.97
  • 52 Week High
  • ALTO $2.05
  • SLN $24.38
  • Technical
  • Relative Strength Index (RSI)
  • ALTO 24.45
  • SLN 49.25
  • Support Level
  • ALTO $0.78
  • SLN $2.63
  • Resistance Level
  • ALTO $0.90
  • SLN $2.95
  • Average True Range (ATR)
  • ALTO 0.07
  • SLN 0.43
  • MACD
  • ALTO -0.01
  • SLN 0.11
  • Stochastic Oscillator
  • ALTO 9.52
  • SLN 72.67

About ALTO Alto Ingredients Inc.

Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include major food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Other production. The Marketing and distribution segment participates in marketing and merchant trading for alcohols and essential ingredients; Pekin Campus produces and sells products produced at the company's Pekin, Illinois, campus, and about half of the firm's revenue flows from this segment. Other production makes and sells from the company's other production facilities.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: